ChemBK
  • Home
  • Product Category
  • CHN
  1. Home
  2. CAS 1491917-83-9
  3. Supplier List
  4. MedChemExpress (MCE)
  5. Signaling Pathways
  6. IMMU-132 (solution)

Request for quotation








Supplier Contact

Supplier NameMedChemExpress (MCE)
Contactsales
Tel609-228-6898
Mobile609-228-6898
QQ
Emailsales@medchemexpress.com; tech@medchemexpress.com
Websitehttps://www.medchemexpress.com/
Wechat
Product NameSatralizumab Linker
SynonymsSatralizumab Linker;Sacituzumab Govitecan
CAS1491917-83-9
EINECS
Chemical Formula
Molecular Weight
inchi
Package1 mg
PriceEmail to quote
DescriptionsSacituzumab govitecan (solution)

Sacituzumab govitecan (solution)

MedChemExpress (MCE)

HY-132254A

1491917-83-9

IMMU-132 (solution)

96.61%

-80°C, protect from light

Shipping with dry ice.

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity.

Sacituzumab govitecan (10 µM

Descriptions

Sacituzumab govitecan (solution)

Sacituzumab govitecan (solution)

MedChemExpress (MCE)

HY-132254A

1491917-83-9

IMMU-132 (solution)

96.61%

-80°C, protect from light

Shipping with dry ice.

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity.

Sacituzumab govitecan (10 µM
48 h) upregulates the early pro-apoptotic signaling markers (cleaved caspase3/7, cleaved PARP, p53 and p21), causes PARP cleavage and apoptosis[3].

Sacituzumab govitecan (IMMU-132) (17.5 mg/kg
twice weekly for 4 weeks) produces significant antitumor effects in mice bearing human gastric cancer xenografts[1].

| | | |

| | | | | |



[1]. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20
26(5):919-31.
[Content Brief]

[2]. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10
11(10):942]. Oncotarget. 2015
6(26):22496-22512.
[Content Brief]

[3]. Cardillo TM, et al., Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20
26(5):919-31.
[Content Brief]

Supplier Websitehttps://www.medchemexpress.com/sacituzumab-govitecan-solution.html
Last Update2025-05-21 16:50:25
MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-05-21 16:50:25

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-05-21 16:50:25

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-05-21 16:50:25

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-05-21 16:50:25

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-05-21 16:50:25

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-05-21 16:50:25

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-05-21 16:50:25

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-05-21 16:50:25
  • Home
  • Product Category

© 2015 ChemBK.com All Rights Reserved | Build: 20150530002